• Publications
  • Influence
Multiple Cancer Testis Antigens Function To Support Tumor Cell Mitotic Fidelity
TLDR
It is demonstrated that combining paclitaxel with a small-molecule inhibitor of the gametogenic and tumor cell mitotic protein TACC3 leads to enhanced centrosomal abnormalities, activation of death programs, and loss of anchorage-independent growth.
Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation.
TLDR
It is proposed that the codependent relationship of ACRBP and NuMA in cancer cells reflects their passage through a selection bottleneck during tumor evolution, one which requires the acquisition of traits that normalize mitotic perturbations that originally drove the plasticity of a preneoplastic genome.
Minority-variant pfcrt K76T mutations and chloroquine resistance, Malawi.
TLDR
A multiple site-specific heteroduplex tracking assay (MSS-HTA) is developed that can detect pfcrt 76T mutant parasites consisting of as little as 1% of the parasite population, suggesting that PCR-undetectable drug-resistant genotypes may be present in disease-endemic populations.
Mechanisms promoting escape from mitotic stress-induced tumor cell death.
TLDR
It is reported that intrinsic resistance to paclitaxel in NSCLC occurs at a cell-autonomous level because of the uncoupling of mitotic defects from apoptosis, and hypothesize that tumor evolution selects for a permissive mitotic checkpoint, which may promote survival despite chromosome segregation errors.
Symplekin Specifies Mitotic Fidelity by Supporting Microtubule Dynamics
TLDR
A high-resolution phenotypic analysis is performed to reveal the mechanistic underpinnings by which symplekin depletion collaborates with paclitaxel and demonstrates a critical connection between the polyadenylation machinery and mitosis.
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
TLDR
An overview of T cell costimulation by CD28 and 4-1BB is provided and, using the available preclinical and clinical data, the efficacy and toxicity profiles associated with CARs containing either costimulatory domain are compared.
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
TLDR
This work provides the longest follow-up of patients in remission after anti-CD19 CAR T-cell therapy, and complete remissions of a variety of B-cell malignancies lasting ≥ 3 years occurred after 51% of evaluable CAR T cells.
...
1
2
...